In multiple myeloma, on the other hand, although PD-L1 expression on plasma cells and dendritic cells has been reported [23], several anti-PD1 Phase 3 clinical trials have been put on hold by the United States Food and Drug Administration for lack of efficacy and excessive or unpredictable toxicity [31]. This evidence concerns the gene CD274 and plasma cell myeloma.